Achilles Therapeutics Company Overview
About Achilles Therapeutics
Achilles Therapeutics PLC ADR (NASDAQ:ACHL) is a biotechnology firm dedicated to developing next-generation, patient-specific therapies that target cancer. The company's innovative approach focuses on harnessing the power of T-cell therapies to treat solid tumors, aiming to create treatments that are more effective and personalized. Achilles Therapeutics is at the forefront of identifying and utilizing clonal neoantigens, which are unique to each tumor, to activate the immune system specifically against cancer cells, leaving healthy cells untouched. Their pipeline includes projects for various types of cancer, with objectives aimed at significantly improving patient outcomes. Through cutting-edge research and clinical trials, Achilles Therapeutics is committed to advancing the fight against cancer with personalized immunotherapies.
Snapshot
Operations
Produtos e/ou serviços de Achilles Therapeutics
- Clonal Neoantigen TCR T cell therapies target and destroy tumor cells by focusing on unique neoantigens from individual cancer mutations.
- Personalized cancer vaccines aim to prime the immune system against specific tumor neoantigens to prevent cancer recurrence.
- Biomarker discovery platforms for identifying unique cancer neoantigens ensure targeted and personalized therapeutic approaches.
- Advanced manufacturing processes for T-cell therapies streamline production, ensuring rapid delivery of personalized treatments to patients.
- Collaborations with biotech and pharmaceutical companies to expand research, development, and distribution capacities for next-generation cancer therapies.
- Patient access programs designed to make innovative treatments more accessible, supporting those with unmet medical needs in oncology.
equipe executiva do Achilles Therapeutics
- Dr. Iraj Ali Ph.D.Chief Executive Officer
- Dr. Sergio A. Quezada Ph.D.Founder
- Mr. Robert CouttsCFO & Director
- Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D.Founder & Member of Scientific Advisory Board
- Dr. Charles Swanton FMEDSCI, M.D., Ph.D.Founder & Member of Scientific Advisory Board
- Mr. Lee M. SternVice President of Investor Relations & External Communications
- Mr. Daniel Carey Cazel HoodGeneral Counsel, Company Secretary & Director
- Julia WilsonHead of Communications
- Mr. Tariq AhmedExecutive Vice President of People